Enfuvirtide, a New Fusion Inhibitor for Therapy of Human Immunodeficiency Virus Infection

Pharmacotherapy

Volumn 24, Issue 2 I, 2004, Pages 198-211

  Hardy, Hélène ^a   Skolnik, Paul R ^a  

^a NONE

Author keywords

Antiretroviral therapy; Clinical trials; Enfuvirtide; Fusion inhibitor; HRI derived fusion peptide inhibitor; Injection site reactions; T 20

Indexed keywords

ABACAVIR; AMPRENAVIR; EFAVIRENZ; ENFUVIRTIDE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANXIETY DISORDER; ASTHENIA; BACTERIAL PNEUMONIA; BRONCHITIS; CLINICAL TRIAL; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FATIGUE; FEVER; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MULTICENTER STUDY; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRURITUS; REVIEW; SINUSITIS; THRUSH; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; PEPTIDE FRAGMENTS;

EID: 1142310723     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.2.198.33141     Document Type: Review

References (45)

1. Palella FR Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV outpatient study investigators. N Engl J Med 1998;338:856-60.
2. Dieleman JP, Jambroes M, Gyssens IG, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The Athena cohort. AIDS 2002;16:737-45.
3. Yeni PG, Hammer SM, Cooper DA, et al. Antiretroviral treatment for adult HIV infection in 2002. JAMA 2002;288:222-35.
4. Schambelan M, Benson CA, Carr A. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31(3):257-75.
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94.
6. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-drug resistance among recently infected persons. JAMA 2002;288:181-8.
7. Roche Pharmaceuticals. Fuzeon (enfuvirtide) package insert. Nutley, NJ; March 2003.
8. O'Brien WA. New classes of HIV drugs on the horizon. AIDS Reader 2003;13(3):S4-8.
9. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chemother 2003;51:213-17.
10. Labranche C, Galasso G, Moore J, et al. HIV fusion and its inhibition. Antiviral Res 2001;50:95-115.
11. Wild C, Shugars D, Greenwell T, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1993;91:9770-4.
12. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993;9:1051-3.
13. Barney S, Guthrie K, Davis D, et al. Pentafuside, a novel inhibitor of HIV-1 and infections, is synergistic when used in combination with reverse transcriptase and protease inhibitors in vitro. Presented at the 11th international conference on antiviral research, San Diego, April 5-10, 1998.
14. Tremblay C, Kollman C, Giguel F, et al. Strong in vitro synergy between the fusion inhibitor T-20 and CXCR4 blocker AMD-3100. Presented at the 7th conference on retroviruses and opportunistic infections, San Francisco, January 30-February 4, 2000.
15. Kilby JM, Hopkins S, Venetta T, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med 1998;4:1302-7.
16. Kilby JM, Lalezari J, Eron J, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide, a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18:685-93.
17. Lalezari J, Eron J, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy-T20-205. AIDS 2003;17:691-8.
18. Lalezari J, Dejesus E, Northfelt D, et al. A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naive patients infected with HIV-1. Presented at the 9th conference on retroviruses and opportunistic infections, Seattle, WA, February 24-28, 2002.
19. Wheat LJ, Lalezari J, Kilby M, et al. Forty-eight week assessment of high strength T-20 in multi-class experienced patients. Presented at the 9th conference on retroviruses and opportunistic infections, Seattle, WA, February 24-28, 2002.
20. Zhang X, Nieforth K, Lang JM, et al. Pharmacokinetics of plasma T-20 after subcutaneous administration to patients with HIV: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002;72:10-19.
21. Melby T, Sista P, Nelson E, et al. Virological characterization of patients through 48 weeks in T20-205 who acquired enfuvirtide resistance-associated mutations during prior short-term enfuvirtide monotherapy [poster]. Presented at the XI international HIV drug resistance workshop: basic principles and clinical implications, Seville, Spain, July 2-5, 2002.
22. Patel IH, Lalezari J, Dorr A, et al. Enfuvirtide is optimally absorbed from three different subcutaneous injection sites [poster]. Presented at the XIV international AIDS conference, Barcelona, Spain, July 7-12, 2002.
23. Roche Pharmaceuticals. Investigator brochure T-20 (Ro 29-9800), 5th version. Nutley, NJ; 2002.
24. Bellibas SE, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric HIV infected patients receiving combination therapy. Presented at the 2nd international AIDs society conference, Paris, France, July 13-16, 2003.
25. Boyd M, Ruxrungtham K, Zhang X, et al. Enfuvirtide-investigations on the drug interactions potential in HIV-infected patients [poster]. Presented at the 10th conference on retroviruses and opportunistic infections, Boston, February 10-14, 2003.
26. McKerrow G. 6th international congress on drug therapy in HIV infection, November 17-21, 2002, Glasgow, United Kingdom [conference report]. HIV Treat Bull 2003;4(1):15. Available from http://www.i-Base.org.uk. Accessed September 15, 2003.
27. Lalezari J, Henry K, O'Hearn M, et al. The TORO 1 study group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
28. Lazzarin A, Boneventura C, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia (TORO 2). N Engl J Med 2003;348:2186-95.
29. Delfraissy JF, Montaner J, Eron J, et al. Summary of pooled efficacy and safety data analyses of enfuvirtide treatment for 24 weeks in TORO 1 and TORO 2 phase III trials in highly antiretroviral treatment-experienced patients [poster]. Presented at the 10th conference on retroviruses and opportunistic infections, Boston, February 10-14, 2003.
30. Katlama C, Arasteh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. Presented at the 2nd international AIDS society conference, Paris, France, July 13-16, 2003.
31. Montaner J, DeMasi R, Delehanty J, et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. Presented at the 2nd international AIDS society conference, Paris, France, July 13-16, 2003.
32. Daviss WB, Coon H, Whitehead P, et al. Predicting diabetic control from competence, adherence, adjustment, and psychopathology. J Am Acad Child Adolesc Psychiatry 1995;34:1929-36.
33. Walmsley S, Henry K, Katlama C, et al. Lack of influence of gp41 antibodies that cross-react with enfuvirtide on the efficacy and safety of enfuvirtide in TORO 1 and TORO 2 phase III trials [poster]. Presented at the 10th conference on retroviruses and opportunistic infections, Boston, February 10-14, 2003.
34. Kosel B, Church J, Cunningham C, et al. Pharmacokinetics of selected doses of T-20, a fusion inhibitor, in HIV-1 infected children. Presented at the 8th conference on retroviruses and opportunistic infections, Chicago, February 4-8, 2001.
35. Bellibas SE, Pepper T, Dorr A, et al. Pharmacokinetics and safety of 2 mg/kg enfuvirtide in combination therapy in HIV infected children and adolescents [poster]. Presented at the XIV international AIDS conference, Barcelona, Spain, July 7-12, 2002.
36. Rimsky L, Shugars D, Matthews T. Determinants of HIV type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-93.
37. Sista P, Melby T, Greenberg M, et al. Characterization of baseline and treatment-emergent resistance to enfuvirtide observed in phase II clinic trials: substitutions in gp41 amino acids (36-45) and enfuvirtide susceptibility of virus isolates [abstr]. Antiviral Ther 2002;7:S16.
38. Mink M, Greenberg M, Mosier S, et al. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility of T-20 in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3 [abstr]. Antiviral Ther 2002;7:S17.
39. Lu J, Cammack N, Kuritzkes D. Fitness of HIV-1 clinical isolates resistant to enfuvirtide [abstr]. Antiviral Ther 2002;7:S56.
40. Sista P. In vitro antiviral activity of T-20 against HIV-1 carrying resistance mutations to reverse transcriptase and protease inhibitors. Investigator brochure, version 5, research report 1007507. Nutley, NJ: Roche Pharmaceuticals, January 2002.
41. Greenberg M, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. Presented at the 10th conference on retroviruses and opportunistic infections, Boston, February 10-14, 2003.
42. Ball R, Kinchelow T, for the ISR Substudy Group. Pathology of injection site reactions with enfuvirtide (T-20) [poster]. Presented at the 10th conference on retroviruses and opportunistic infections, Boston, February 10-14, 2003.
43. Cohen C, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activity of daily living. AIDS Patient Care STDs 2002;16(7):327-35.
44. Green J, Salgo MP, Delehanty J. Patient survey on injection of enfuvirtide: ease of use and impact on activities [poster]. Presented at the XIV international AIDS conference, Barcelona, Spain, July 7-12, 2002.
45. Cohen C, Clumeck N, Molina JM, et al. Impact of enfuvirtide on health-related quality of life. Presented at the 2nd international AIDS society conference, Paris, France, July 13-16, 2003.